MCM
TAK icon

Manchester Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Manchester Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.5K Hold
4,649
– – 0.01% 433
2026
Q1 		$86.1K Hold
4,649
– – 0.01% 388
2025
Q4 		$72.5K Buy
4,649
+2,220
+91% +$31.7K 0.01% 426
2025
Q3 		$35.6K Buy
2,429
+2
+0.1% +$30 ﹤0.01% 638
2025
Q2 		$37.5K Buy
2,427
+189
+8% +$2.79K ﹤0.01% 620
2025
Q1 		$33.3K Buy
2,238
+46
+2% +$645 ﹤0.01% 624
2024
Q4 		$29K Buy
2,192
+161
+8% +$2.21K ﹤0.01% 652
2024
Q3 		$28.9K Buy
2,031
+215
+12% +$3.05K ﹤0.01% 643
2024
Q2 		$23.5K Buy
1,816
+1,334
+277% +$17.7K ﹤0.01% 636
2024
Q1 		$6.7K Hold
482
– – ﹤0.01% 689
2023
Q4 		$6.88K Sell
482
-183
-28% -$2.6K ﹤0.01% 657
2023
Q3 		$10.3K Sell
665
-53
-7% -$820 ﹤0.01% 580
2023
Q2 		$11.3K Buy
718
+153
+27% +$2.51K ﹤0.01% 537
2023
Q1 		$9.31K Hold
565
– – ﹤0.01% 555
2022
Q4 		$8.81K Buy
565
+62
+12% +$866 ﹤0.01% 476
2022
Q3 		$7K Sell
503
-325
-39% -$4.52K ﹤0.01% 483
2022
Q2 		$12K Sell
828
-4
-0.5% -$57 ﹤0.01% 464
2022
Q1 		$12K Buy
832
+190
+30% +$2.79K ﹤0.01% 524
2021
Q4 		$9K Sell
642
-15
-2% -$210 ﹤0.01% 580
2021
Q3 		$11K Buy
657
+159
+32% +$2.67K ﹤0.01% 582
2021
Q2 		$8K Sell
498
-170
-25% -$2.89K ﹤0.01% 520
2021
Q1 		$12K Hold
668
– – ﹤0.01% 472
2020
Q4 		$12K Hold
668
– – ﹤0.01% 471
2020
Q3 		$12K Hold
668
– – ﹤0.01% 419
2020
Q2 		$12K Hold
668
– – ﹤0.01% 464
2020
Q1 		$10K Hold
668
– – ﹤0.01% 468
2019
Q4 		$13K Buy
+668
New +$12.8K ﹤0.01% 456

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Manchester Capital Management's TAK Position: Q2 2026 in Review

Manchester Capital Management held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 4,649 shares worth $74.5K. The position accounts for 0.01% of the portfolio, ranked #433.

Manchester Capital Management first reported a position in TAK in Q4 2019 and has held it in 27 quarters since. The position peaked at $86.1K in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Manchester Capital Management held 4,649 shares of Takeda Pharmaceutical worth $74.5K as of Q2 2026.
  • Manchester Capital Management left its Takeda Pharmaceutical share count unchanged in Q2 2026.
  • Takeda Pharmaceutical made up 0.01% of Manchester Capital Management's portfolio in Q2 2026, its #433 holding.
  • Manchester Capital Management first reported a position in Takeda Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • Manchester Capital Management's Takeda Pharmaceutical position peaked at $86.1K in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.